- Open enrollment for the second year of Obamacare individual health coverage brought in 462,125 people who chose their health plans in its first week, nearly half of whom were first-time customers, the U.S. government said on Wednesday.
WASHINGTON - GlaxoSmithKline won U.S. antitrust approval to buy Novartis AG's vaccine business, with the exception of influenza vaccines, the two companies said on Wednesday.
(Reuters Health) - Rates of breast cancer recurrence fell by half or more between the 1980s and the early 2000s - likely due to improved treatments and increased screenings, according to a new study from Canada.
WASHINGTON - Six of the nine Ebola patients treated in the United States in recent months met for the first time on Wednesday, saying their ordeals fighting the virus have not dampened their desire to help others and that they are grateful to be alive.
ATLANTA - Cigarette smoking among U.S. adults last year touched its lowest on record, a drop spurred by higher prices, smoke-free policies and anti-smoking campaigns, the Centers for Disease Control and Prevention said on Wednesday.
NEW YORK - An experimental Ebola vaccine made by GlaxoSmithKline caused no serious side effects and produced an immune response in all 20 healthy volunteers who received it in an early-stage clinical trial, scientists reported on Wednesday in the New England Journal of Medicine.
DAKAR - Sierra Leone appealed to the United States on Wednesday to send military aid to help it battle Ebola as it falls behind its West African neighbors Guinea and Liberia in the fight against the virus.
GENEVA - The death toll in the world's worst Ebola epidemic has risen to 5,689 out of 15,935 cases reported in eight countries by Nov. 23, the World Health Organization said on Wednesday. | Video
(Reuters Health) – A classical set of celiac disease symptoms no longer reflects the profile of most newly-diagnosed patients, according to a new study from Italy.
- The U.S. Food and Drug Administration rejected Avanir Pharmaceuticals Inc's migraine drug device, a few weeks after the regulator had raised questions regarding some data submitted as part of the marketing application.